Clinical Neuroscience

[The role of Ospolot in the treatment of childhood epilepsy]

KISZELY Katalin1

FEBRUARY 01, 1966

Clinical Neuroscience - 1966;12(02)

[Based on our observation of 20 patients treated with Ospolot, we found that Ospolot is suitable for the treatment of psychomotor epilepsy. Because of its relatively frequent side effects, it should only be introduced in cases resistant to other therapies, initially in combination with other anticonvulsant drugs, under hospital observation. It should be tried in psychomotor seizures in which the EEG also indicates temporal focus. If focal convulsive activity on EEG is reduced or eliminated in response to medication, the clinical picture usually improves. ]

AFFILIATIONS

  1. Országos Ideg-és Elmegyógyintézet Gyerekosztálya

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[Curative experiments on depression patients with Elysione]

NYÍRŐ Gyula, IRÁNYI Jenőné

[Authors conducted therapy trials with low doses of Elysione in 50 depressed male patients. They observed a reaction to Elysione in nearly 500 cases. 3 mg induced well-appreciated euphoria, 4-10 mg induced psychotomimetic, neurological and vegetative symptoms. Cure courses (one injection per day for 7, 10 and 14 days) in depressed patients proved to be of therapeutic value. Before its practical use, a large number of trials should be carried out and side effects should be eliminated by modifying the chemical structure, and it should be possible to use it per os.]

Clinical Neuroscience

[Measurement of muscle action potential propagation velocity in clinical patient material]

HASZNOS Tivadar, FENYŐ Egon

[The authors investigated the propagation velocity of muscle action potentials in 53 normal individuals, 18 neurogenic lesions, 15 patients with myopathy and 2 patients with myasthenia. The muscle conduction velocity was assessed in the m. deltoideus, m. biceps brachii, m. flexor digiti V., m. tibialis anterior and m. quadriceps. Stimulation was performed with two needle electrodes in bipolar mode and recording with a concentric bipolar electrode. The muscle conduction velocity was 4.48 + 0.09 m/sec in the normal control group, 3.28 + 0.21 m/sec in neurogenic lesion and 3.07 + 0.18 m/sec in myopathy patients. The difference was highly significant in both groups (P < 0.001). The muscle conduction velocity within the neurogenic group was found to be the same in peripheral nerve lesion (3.29 = 0.33 m/sec) and anterior horn lesion (3.25 + 0.26 m/sec). In the neurogenic cases, we found a conduction velocity value below 3.5 m/sec in 68% of the clinically affected muscles. A conduction velocity below 3.5 m/sec was observed in 66.6% of myopathic patients. Conduction velocity values found in Duchenne-type dystrophia musculorum progressiva, dystrophya myotonic, thyrotoxic myopathy, myopathia tarda and polymyositis were significantly different from normal controls. In dystrophia musculorum progressiva in facioscapulo humeralis and limb girdle, the deviation from normal control was not significant. In myasthenia cases, muscle conduction velocity was normal (4.57 I 0.21 m/sec). The authors discuss the factors that may lead to a decrease in muscle conduction velocity in neurogenic and myogenic laesio. ]

Clinical Neuroscience

[Epidermoid tumours (cholesteatomas) in the central nervous system]

BARADNAY Gyula, SZANDTNER György, HOFFMANN János

[Authors report 3 operated and 2 autopsy cases of central nervous system epidermoid tumours. Two of their operated patients were lost, the third one is symptom and complaint free since surgery - 2 years ago. They also describe the views on the aetiology of epidermoid tumours, the macro- and micromorphology of these tumours, their clinical symptoms and the surgical treatment options. ]

Clinical Neuroscience

[Changes in serum arginine levels in patients with epilepsy]

SZILÁGYI Á. Katalin, PATAKY István

[Authors investigating serum arginine levels in a mixed neuropsychiatric patient population found that the epileptic patient group had significantly lower levels compared to both normal controls and all other patients. No correlation was found between clinical presentation or pathogenetic factors and the development of arginine levels. A correlation between the nature of brain electrical activity and arginine levels, not statistically verifiable, seems to be observed. ]

Clinical Neuroscience

[Report from four months study trip in the Netherlands (Wassenaari)]

LEEL-ŐSSY Lóránt

[The author reports on his four-month study trip to the Netherlands.]

All articles in the issue

Related contents

Clinical Neuroscience

Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study

NÉMETH Klára Zsófia, SZÛCS Anna , VITRAI József , JUHÁSZ Dóra , NÉMETH Pál János , HOLLÓ András

We aimed to investigate the association between fluoxetine use and the survival of hospitalised coronavirus disease (COVID-19) pneumonia patients. This retrospective case-control study used data extracted from the medical records of adult patients hospitalised with moderate or severe COVID-19 pneumonia at the Uzsoki Teaching Hospital of the Semmelweis University in Budapest, Hungary between 17 March and 22 April 2021. As a part of standard medical treatment, patients received anti-COVID-19 therapies as favipiravir, remdesivir, baricitinib or a combination of these drugs; and 110 of them received 20 mg fluoxetine capsules once daily as an adjuvant medication. Multivariable logistic regression was used to evaluate the association between fluoxetine use and mortality. For excluding a fluoxetine-selection bias potentially influencing our results, we compared baseline prognostic markers in the two groups treated versus not treated with fluoxetine. Out of the 269 participants, 205 (76.2%) survived and 64 (23.8%) died between days 2 and 28 after hospitalisation. Greater age (OR [95% CI] 1.08 [1.05–1.11], p<0.001), radiographic severity based on chest X-ray (OR [95% CI] 2.03 [1.27–3.25], p=0.003) and higher score of shortened National Early Warning Score (sNEWS) (OR [95% CI] 1.20 [1.01-1.43], p=0.04) were associated with higher mortality. Fluoxetine use was associated with an important (70%) decrease of mortality (OR [95% CI] 0.33 [0.16–0.68], p=0.002) compared to the non-fluoxetine group. Age, gender, LDH, CRP, and D-dimer levels, sNEWS, Chest X-ray score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.

Clinical Neuroscience

[The role of sleep in the relational memory processes ]

CSÁBI Eszter, ZÁMBÓ Ágnes, PROKECZ Lídia

[A growing body of evidence suggests that sleep plays an essential role in the consolidation of different memory systems, but less is known about the beneficial effect of sleep on relational memory processes and the recognition of emotional facial expressions, however, it is a fundamental cognitive skill in human everyday life. Thus, the study aims to investigate the effect of timing of learning and the role of sleep in relational memory processes. 84 young adults (average age: 22.36 (SD: 3.22), 21 male/63 female) participated in our study, divided into two groups: evening group and morning group indicating the time of learning. We used the face-name task to measure relational memory and facial expression recognition. There were two sessions for both groups: the immediate testing phase and the delayed retesting phase, separated by 24 hours. 84 young adults (average age: 22.36 (SD: 3.22), 21 male/63 female) participated in our study, divided into two groups: evening group and morning group indicating the time of learning. We used the face-name task to measure relational memory and facial expression recognition. There were two sessions for both groups: the immediate testing phase and the delayed retesting phase, separated by 24 hours. Our results suggest that the timing of learning and sleep plays an important role in the stabilizing process of memory representation to resist against forgetting.]

Clinical Neuroscience

Evaluation of the effectiveness of transforaminal epidural steroid injection in far lateral lumbar disc herniations

EVRAN Sevket, KATAR Salim

Far lateral lumbar disc herniations (FLDH) consist approximately 0.7-12% of all lumbar disc herniations. Compared to the more common central and paramedian lumbar disc herniations, they cause more severe and persistent radicular pain due to direct compression of the nerve root and dorsal root ganglion. In patients who do not respond to conservative treatments such as medical treatment and physical therapy, and have not developed neurological deficits, it is difficult to decide on surgical treatment because of the nerve root damage and spinal instability risk due to disruption of facet joint integrity. In this study, we aimed to evaluate the effect of transforaminal epidural steroid injection (TFESI) on the improvement of both pain control and functional capacity in patients with FLDH. A total of 37 patients who had radicular pain caused by far lateral disc herniation which is visible in their lumbar magnetic resonance imaging (MRI) scan, had no neurological deficit and did not respond to conservative treatment, were included the study. TFESI was applied to patients by preganglionic approach. Pre-treatment Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) scores of the patients were compared with the 3rd week, 3rd month and 6th month scores after the procedure. The mean initial VAS score was 8.63 ± 0.55, while it was 3.84 ± 1.66, 5.09 ± 0.85, 4.56 ± 1.66 at the 3rd week, 3rd month and 6th month controls, respectively. This decrease in the VAS score was found statistically significant (p = 0.001). ODI score with baseline mean value of 52.38 ± 6.84 was found to be 18.56 ± 4.95 at the 3rd week, 37.41 ± 14.1 at the 3rd month and 34.88 ± 14.33 at the 6th month. This downtrend of pa­tient’s ODI scores was found statistically significant (p = 0.001). This study has demonstrated that TFESI is an effective method for gaining increased functional capacity and pain control in the treatment of patients who are not suitable for surgical treatment with radicular complaints due to far lateral lumbar disc hernia.

Clinical Neuroscience

Comparison of direct costs of percutaneous full-endoscopic interlaminar lumbar discectomy and microdiscectomy: Results from Turkey

ÜNSAL Ünlü Ülkün, ŞENTÜRK Salim

Microdiscectomy (MD) is a stan­dard technique for the surgical treatment of lumbar disc herniation (LDH). Uniportal percutaneous full-endoscopic in­terlaminar lumbar discectomy (PELD) is another surgical op­tion that has become popular owing to reports of shorter hos­pitalization and earlier functional recovery. There are very few articles analyzing the total costs of these two techniques. The purpose of this study was to compare total hospital costs among microdiscectomy (MD) and uniportal percutaneous full-endoscopic interlaminar lumbar discectomy (PELD). Forty patients aged between 22-70 years who underwent PELD or MD with different anesthesia techniques were divided into four groups: (i) PELD-local anesthesia (PELD-Local) (n=10), (ii) PELD-general anesthesia (PELD-General) (n=10), (iii) MD-spinal anesthesia (MD-Spinal) (n=10), (iv) MD-general anesthesia (MD-General) (n=10). Health care costs were defined as the sum of direct costs. Data were then analyzed based on anesthetic modality to produce a direct cost evaluation. Direct costs were compared statistically between MD and PELD groups. The sum of total costs was $1,249.50 in the PELD-Local group, $1,741.50 in the PELD-General group, $2,015.60 in the MD-Spinal group, and $2,348.70 in the MD-General group. The sum of total costs was higher in the MD-Spinal and MD-General groups than in the PELD-Local and PELD-General groups. The costs of surgical operation, surgical equipment, anesthesia (anesthetist’s costs), hospital stay, anesthetic drugs and materials, laboratory wor­kup, nur­sing care, and postoperative me­dication diffe­red significantly among the two main groups (PELD-MD) (p<0.01). This study demonstrated that PELD is less costly than MD.

Clinical Neuroscience

Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias

BALÁZS Nóra , BERECZKI Dániel, KOVÁCS Tibor

In aging societies, the morbidity and mortality of dementia is increasing at a significant rate, thereby imposing burden on healthcare, economy and the society as well. Patients’ and caregivers’ quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer’s therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer’s dementias too. The aim of our work was to provide a comprehensive summary about the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s and non-Alzheimers’s dementias.